A lab technician inspects filled vials of investigational coronavirus disease (COVID-19) treatment drug remdesivir at a Gilead Sciences facility in La Verne, California, U.S. March 11, 2020. Picture taken March 11, 2020.
Gilead Sciences Inc | Reuters
Gilead Sciences published new data Friday on its antiviral drug remdesivir that shows it reduced the risk of death for severely sick coronavirus patients by 62% compared with standard care alone.
The findings are being presented at the Virtual Covid-19 Conference as part of the 23rd International AIDS Conference, the company said.
Shares of Gilead rose almost 3% in premarket trading Friday on the news.
The company said it collected the data from a comparative analysis using both patients in its phase three trial as well as patients from “a real-world retrospective cohort of patients.”
Gilead said its findings warrant more study in additional trials.
“We are working to broaden our understanding of the full utility of remdesivir,” Gilead’s Chief Medical Officer Dr. Merdad Parsey said in a statement. “To address the urgency of the continuing pandemic, we are sharing data with the research community as quickly as possible with the goal of providing transparent and timely updates on new developments with remdesivir.”
This is breaking news. Please check back for updates.
Source: Business - cnbc.com
